HIMS
$24.98
Hims & Hers Health, Inc.
Recent News
Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...
Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform. Management noted that as part of this […]
Hims And Hers Health Pushes Into Complex Care And Global Growth
Hims & Hers Health (NYSE:HIMS) is expanding into complex health categories such as cancer care, longevity treatments, and at-home lab testing. The company is pursuing these areas through acquisitions that aim to bring more of the care journey onto its own platform. Hims & Hers Health is also ramping up international expansion, moving beyond its core US telehealth base. The shift marks a move away from a primary focus on telehealth visits and weight loss drugs toward a broader digital health...
HIMS Expands Personalized Digital Healthcare Access and Services
Hims & Hers expands its digital care platform with labs tracking, multi-cancer screening access and broader treatments as it scales personalized healthcare globally.
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.